Abstract
Introduction: This phase II trial was conducted to assess the efficacy and safety of 10-Ethyl-10-Deaza-Aminopterin (10-EDAM), a folate antagonist, in metastatic breast cancer patients who had received no more than one prior chemotherapy regimen. Methods: Fifty-five patients were treated on an initial weekly dose 80 mg/m2 of 10-EDAM. Patients who had received a prior chemotherapy regimen in the adjuvant setting (group 1) were considered separately from patients who had received a prior chemotherapy regimen in the metastatic setting (group 2). Results: The response rate for both groups combined was 18%, and median time to progression was 3 months. Median overall survival was 12 months. Treatment was associated with common chemotherapy-related toxicities, such as 25% grade three or four neutropenia and 20% grade three or four stomatitis. Conclusion: In patients with metastatic breast cancer who had received one prior chemotherapy regimen, 10-EDAM was well tolerated. In general, while definite antitumor activity was documented, time to progression was brief.
Original language | English (US) |
---|---|
Pages (from-to) | 61-67 |
Number of pages | 7 |
Journal | Cancer chemotherapy and pharmacology |
Volume | 60 |
Issue number | 1 |
DOIs | |
State | Published - Jun 2007 |
Keywords
- Chemotherapy
- Clinical trial
- Folic acid antagonist
- Toxicity
ASJC Scopus subject areas
- Oncology
- Toxicology
- Pharmacology
- Cancer Research
- Pharmacology (medical)
MD Anderson CCSG core facilities
- Clinical Trials Office